RADX
Radiopharm Theranostics Limited
NASDAQ · Healthcare · Biotechnology · AU
$2.08
−3.48%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +110.0%
- EBITDA
- -75.1%
- EBIT
- -75.1%
- Net income
- -40.7%
- EPS
- +13.6%
- Free cash flow
- +100.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026